Sequence Quantification

ⓖSEQ is our exclusive method for the amplification and sequencing of DNA from embryo biopsies. This method provides an unparalleled ability to accurately quantify chromosomes for aneuploidy screening, as well as genotype single-gene and polygenic disorders.
Compared to the leading aneuploidy screens on the market, ⓖSEQ is:
  • Less expensive.
  • Less error-prone.
  • Significantly easier to perform.

Pre-Implantation Genomic Testing

EPⓖT enables the routine, inexpensive evaluation of hundreds of thousands of genetic variants through a novel combination of embryo genotyping methods. Among the genetic disorders whose phenotype risk can routinely be diagnosed by EPⓖT are:
  • 300+ common single-gene disorders, such as Cystic Fibrosis, Thalassemia, BRCA, Sickle Cell Anemia, and Gaucher Disease
  • Polygenic Disease Risk, such as risk for Type 1 and Type 2 diabetes, Dwarfism, Hypothyroidism, Mental Disability, Atrial Fibrillation and other Cardiovascular Diseases like CAD, Inflammatory Bowel Disease, and Breast Cancer.

Why Choose
Genomic Prediction?

Genomic Prediction provides advanced genetic testing for IVF. We have developed a novel, genome-wide molecular genotyping methodology for pre-implantation genetic testing of embryos.

Our approach reduces disease risk and improves newborn health outcomes by identifying candidate embryos for implantation which are genetically normal.


(of human disease)


(of human disease)

What the World Says

In 2019, [IVF Couples using EPⓖT] will have an opportunity to give their offspring a greater chance of living a long and healthy life.

The Economist's "The World of 2019"

I take my hat off to what they’re doing, it’s a potential revolution.

Simon Fishel,
president of the Care Fertility Group
clinics in the UK

Latest News